TOKYO, Mar 17 (Pulse News Wire) – Chiome Bioscience Inc. (4583.T) received notification of a patent grant for its humanized DLK-1 antibody, CBA1,205, in Europe.
The patent covers the combination therapy of CBA__NUM_2__ and lenvatinib for treating hepatocellular carcinoma. In xenograft models, the combination demonstrated strong tumor growth inhibition and reduction effects. This patent follows successful filings in Japan and China, with ongoing applications in the United States. It strengthens Chiome's intellectual property portfolio supporting development and licensing activities.
CBA__NUM_2__ targets DLK-1, an antigen found on the surface of solid tumors, particularly liver cancer cells. Currently, Chiome is conducting a Phase 1 clinical trial in Japan targeting patients with hepatocellular carcinoma. Safety and initial efficacy data from this trial will inform potential partnerships with pharmaceutical companies. DLK-1, also known as Delta-like homolog-1, regulates stem cell proliferation and differentiation.
Its presence on liver cancer cells suggests potential as a novel therapeutic target.
🟢 Confidence: High AI-translated content.